NCT00575016 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 28, 2010

Study Completion Date

July 31, 2010

Conditions

Overactive Bladder

Interventions

BIOLOGICAL

Normal saline (Placebo); botulinum toxin Type A (200U)

Placebo injection on Day 1 and botulinum toxin Type A injection 200 U \> Week 12; injection into the detrusor

BIOLOGICAL

botulinum toxin Type A (50U); botulinum toxin Type A (200U)

botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor

BIOLOGICAL

botulinum toxin Type A (100U); botulinum toxin Type A (200U)

botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor

BIOLOGICAL

botulinum toxin Type A (200U)

botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U \> 12 weeks; injections into the detrusor

Trial Locations (6)

Cairo

Thessaloniki

Ahmadābād

Beirut

Belgrade

Ankara